https://glance.eyesoneyecare.com/stories/2023-05-04/endogena-concludes-enrollment-ahead-of-schedule-for-rp-trial/
Endogena concludes enrollment ahead of schedule for RP trial
Phase 1/2a dose expansion trial is assessing the safety and tolerability of EA-2353.
concludesenrollmentaheadschedulerp
https://ophthalmologybreakingnews.com/endogena-therapeutics-receives-fda-fast-track-designation-for-treatment-of-retinitis-pigmentosa
Endogena Receives FDA Fast Tract Designation for RP | OBN
Endogena announced that the US FDA has designated the investigation of its drug EA-2353 for the treatment of RP as a Fast Track development program.
receivesfdafasttractdesignation
https://endogena.com/
endogena therapeutics – endogena.com
therapeutics
https://www.modernretina.com/view/endogena-therapeutics-completes-enrollment-early-for-its-phase-1-2a-trial-of-ea-2353-for-retinitis-pigmentosa
Endogena Therapeutics completes enrollment early for its Phase 1/2a trial of EA-2353 for retinitis...
May 18, 2026 - Endogena Therapeutics Inc. has completed patient enrollment ahead of schedule with a cohort of 14 patients with RP due to any pathologic genetic mutation...